The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?
Open accessAbstract
K2 or Spice products are emerging drugs of abuse that contain synthetic cannabinoids (SCBs). Although assumed by many teens and first time drug users to be a “safe” and “legal” alternative to marijuana, many recent reports indicate that SCBs present in K2 produce toxicity not associated with the primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). This mini-review will summarize recent evidence that use of K2 products poses greater health risks relative to marijuana, and suggest that distinct pharmacological properties and metabolism of SCBs relative to Δ9-THC may contribute to the observed toxicity. Studies reviewed will indicate that in contrast to partial agonist properties of Δ9-THC typically observed in vitro, SCBs in K2 products act as full cannabinoid receptor type 1 (CB1R) and type 2 (CB2R) agonists in both cellular assays and animal studies. Furthermore, unlike Δ9-THC metabolism, several SCB metabolites retain high affinity for, and exhibit a range of intrinsic activities at, CB1 and CB2Rs. Finally, several reports indicate that although quasi-legal SCBs initially evaded detection and legal consequences, these presumed “advantages” have been limited by new legislation and development of product and human testing capabilities. Collectively, evidence reported in this mini-review suggests that K2 products are neither safe nor legal alternatives to marijuana. Instead, enhanced toxicity of K2 products relative to marijuana, perhaps resulting from the combined actions of a complex mixture of different SCBs present and their active metabolites that retain high affinity for CB1 and CB2Rs, highlights the inherent danger that may accompany use of these substances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870
Neubig, R. R., Spedding, M., Kenakin, T., & Christopoulos, A. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.4 · Cited by 665
Hirvonen, J., Goodwin, R. S., Li, C.-T., Terry, G. E., Zoghbi, S. S., Morse, C., Pike, V. W., Volkow, N. D., Huestis, M. A., & Innis, R. B. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.82 · Cited by 587
Cannabis: pharmacology and toxicology in animals and humans
ADAMS, I. B., & MARTIN, B. R. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911115852.x · Cited by 570
The cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
Seely, K. A., Lapoint, J., Moran, J. H., & Fattore, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.017 · Cited by 465
Self-citationBeyond THC: The New Generation of Cannabinoid Designer Drugs
Fattore, L., & Fratta, W. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00060 · Cited by 443
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397
Functional interaction between opioid and cannabinoid receptors in drug self-administration.
Navarro, M., Carrera, M. R. A., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J. A., Gómez, R., del Arco, I., Villanúa, M. A., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05344.2001 · Cited by 378
Tanda, G., Munzar, P., & Goldberg, S. R. (2000) · Nature Neuroscience · doi:10.1038/80577 · Cited by 345
Spice drugs as a new trend: Mode of action, identification and legislation
Vardakou, I., Pistos, C., & Spiliopoulou, C. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.06.002 · Cited by 341
Dresen, S., Ferreirós, N., Pütz, M., Westphal, F., Zimmermann, R., & Auwärter, V. (2010) · Journal of Mass Spectrometry · doi:10.1002/jms.1811 · Cited by 309
Lindigkeit, R., Boehme, A., Eiserloh, I., Luebbecke, M., Wiggermann, M., Ernst, L., & Beuerle, T. (2009) · Forensic Science International · doi:10.1016/j.forsciint.2009.06.008 · Cited by 299
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.
Little, P. J., Compton, D. R., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13256-4 · Cited by 291
A survey study to characterize use of Spice products (synthetic cannabinoids)
Vandrey, R., Dunn, K. E., Fry, J. A., & Girling, E. R. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.011 · Cited by 283
Huestis, M. A. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_23 · Cited by 278
Withdrawal Phenomena and Dependence Syndrome After the Consumption of „Spice Gold“
Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., & Schulz, K. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0464 · Cited by 278
Atwood, B. K., Huffman, J., Straiker, A., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00582.x · Cited by 262
Cannabinoid tolerance and dependence: A review of studies in laboratory animals
GONZALEZ, S., CEBEIRA, M., & FERNANDEZRUIZ, J. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.028 · Cited by 258
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001640 · Cited by 257
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding
Aung, M. M., Griffin, G., Huffman, J. W., Wu, M.-J., Keel, C., Yang, B., Showalter, V. M., Abood, M. E., & Martin, B. R. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00152-0 · Cited by 254
Watanabe, K., Yamaori, S., Funahashi, T., Kimura, T., & Yamamoto, I. (2007) · Life Sciences · doi:10.1016/j.lfs.2006.12.032 · Cited by 236
Gunderson, E. W., Haughey, H. M., Ait‐Daoud, N., Joshi, A. S., & Hart, C. L. (2012) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00240.x · Cited by 226
The behavioral pharmacology of hallucinogens
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.018 · Cited by 225
Self-citationSelf-administration of ?9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys
Justinova, Z., Tanda, G., Redhi, G. H., & Goldberg, S. R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1484-0 · Cited by 220
Detection of JWH-018 metabolites in smoking mixture post-administration urine
Sobolevsky, T. G., Prasolov, I., & Rodchenkov, G. M. (2010) · Forensic Science International · doi:10.1016/j.forsciint.2010.04.003 · Cited by 219
Teske, J., Weller, J.-P., Fieguth, A., et al. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.03.016 · Cited by 216
Paparelli, A., Di Forti, M., Morrison, P. D., & Murray, R. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00001 · Cited by 216
Compton, D. R., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11216-0 · Cited by 215
Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., & Prather, P. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021917 · Cited by 214
Self-citationSevere Toxicity Following Synthetic Cannabinoid Ingestion
Lapoint, J., James, L. P., Moran, C. L., Nelson, L. S., Hoffman, R. S., & Moran, J. H. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.609822 · Cited by 212
Self-citationAllsop, D. J., Norberg, M. M., Copeland, J., Fu, S., & Budney, A. J. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.06.003 · Cited by 205
Cannabinoid Addiction: Behavioral Models and Neural Correlates
Maldonado, R., & Rodrı́guez de Fonseca, F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03326.2002 · Cited by 205
Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice
Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., & Fratta, W. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00052-9 · Cited by 202
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification.
Vanhoutte, P. M., Barnard, E. A., Cosmides, G. J., Humphrey, P. P., Spedding, M., & Godfraind, T. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06779-1 · Cited by 188
Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats
Fattore, L., Cossu, G., Martellotta, C., & Fratta, W. (2001) · Psychopharmacology · doi:10.1007/s002130100734 · Cited by 187
Chimalakonda, K. C., Seely, K. A., Bratton, S. M., Brents, L. K., Moran, C. L., Endres, G. W., James, L. P., Hollenberg, P. F., Prather, P. L., Radominska-Pandya, A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047530 · Cited by 186
Self-citationIntravenous self-administration of drugs in rats.
van Ree, J. M., Slangen, J. L., & de Wied, D. (1978) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31172-9 · Cited by 170
URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products
Uchiyama, N., Kawamura, M., Kikura‐Hanajiri, R., & Goda, Y. (2012) · Forensic Science International · doi:10.1016/j.forsciint.2012.08.047 · Cited by 160
Frost, J. M., Dart, M. J., Tietje, K. R., Garrison, T. R., Grayson, G. K., Daza, A. V., El-Kouhen, O. F., Yao, B. B., Hsieh, G. C., Pai, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901214q · Cited by 156
Dresen, S., Kneisel, S., Weinmann, W., Zimmermann, R., & Auwärter, V. (2011) · Journal of Mass Spectrometry · doi:10.1002/jms.1877 · Cited by 155
Brents, L. K., Gallus‐Zawada, A. E., Radominska-p, A., Vasiljevik, T., Prisinzano, T. E., Fantegrossi, W. E., Moran, J. H., & Prather, P. L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.004 · Cited by 149
Self-citationExpression and Function of Cytochrome P450 in Brain Drug Metabolism
Meyer, R., Gehlhaus, M., Knoth, R., & Volk, B. (2007) · Current Drug Metabolism · doi:10.2174/138920007780655478 · Cited by 145
In vitro phase I metabolism of the synthetic cannabimimetic JWH-018
Wintermeyer, A., Möller, I., Thevis, M., Jübner, M., Beike, J., Rothschild, M. A., & Mercer‐Chalmers‐Bender, K. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4171-0 · Cited by 144
Hutter, M., Broecker, S., Kneisel, S., et al. (2012) · Journal of Mass Spectrometry · doi:10.1002/jms.2026 · Cited by 144
Study of cannabinoid dependence in animals
Maldonado, R. J. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00254-1 · Cited by 136
Esposito, S., Deventer, K., Dumoulin, M., & Van Eenoo, P. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1418 · Cited by 133
Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?
Seely, K. A., Prather, P. L., James, L. P., & Moran, J. H. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.6 · Cited by 133
Self-citationΔ9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication
Balster, R. L., & Prescott, W. R. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80051-x · Cited by 133
Grigoryev, A., Savchuk, S. A., Melnik, A., et al. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.03.034 · Cited by 132
Screening for the synthetic cannabinoid JWH‐018 and its major metabolites in human doping controls
Möller, I., Wintermeyer, A., Mercer‐Chalmers‐Bender, K., et al. (2010) · Drug Testing and Analysis · doi:10.1002/dta.158 · Cited by 128
Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan, F., Compton, D. M., Ward, S. J., Melvin, L. S., & Martin, B. R. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24023-x · Cited by 126
Howlett, A. C., Champion, T. M., Wilken, G. H., & Mechoulam, R. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90056-w · Cited by 126
Sim‐Selley, L. J., & Martin, B. R. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035618 · Cited by 125
1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles
Huffman, J. W., Szklennik, P. V., Almond, A., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.008 · Cited by 125
Wohlfarth, A., Scheidweiler, K. B., Chen, X., et al. (2013) · Analytical Chemistry · doi:10.1021/ac3037365 · Cited by 124
Hudson, S. C., Ramsey, J., King, L. A., Timbers, S., Maynard, S., Dargan, P. I., & Wood, D. M. (2010) · Journal of Analytical Toxicology · doi:10.1093/jat/34.5.252 · Cited by 124
Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol in rhesus monkeys
Harris, R. T., Waters, W., & McLendon, D. M. (1974) · Psychopharmacology · doi:10.1007/bf00426679 · Cited by 120
Griffin, G., Atkinson, P. J., Showalter, V. M., Martin, B. R., & Abood, M. E. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37418-x · Cited by 118
Atwood, B. K., Lee, D., Straiker, A. J., Widlanski, T. S., & Mackie, K. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.066 · Cited by 114
Kacinko, S. L., Xu, A. S., Homan, J. W., et al. (2011) · Journal of Analytical Toxicology · doi:10.1093/anatox/35.7.386 · Cited by 114
The marijuana withdrawal syndrome: Diagnosis and treatment
Haney, M. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0036-1 · Cited by 111
Justinová, Z., Solinas, M., Tanda, G., Redhi, G. H., & Goldberg, S. R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0951-05.2005 · Cited by 108
The Synthetic Cannabinoid Withdrawal Syndrome
Nacca, N. E., Vatti, D., Sullivan, R. W., Sud, P., Su, M. K., & Marraffa, J. M. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31828e1881 · Cited by 107
Synthetic Cannabinoids in Oral Fluid
Coulter, C., Garnier, M., & Moore, C. M. (2011) · Journal of Analytical Toxicology · doi:10.1093/anatox/35.7.424 · Cited by 105
Comparison of “herbal highs” composition
Zuba, D., Byrska, B., & Maciów, M. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4743-7 · Cited by 101
Rajasekaran, M., Brents, L. K., Franks, L. N., Moran, J. H., & Prather, P. L. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.03.012 · Cited by 98
Self-citationSpontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2
Aceto, M. D. G., Scates, S. M., & Martin, B. R. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00873-1 · Cited by 98
Mansbach, R. S., Nicholson, K. L., Martin, B. R., & Balster, R. L. (1994) · Behavioural Pharmacology · doi:10.1097/00008877-199404000-00014 · Cited by 97
K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure
Patton, A. L., Chimalakonda, K. C., Moran, C. L., McCain, K. R., Radominska-p, A., James, L. P., Kokes, C. P., & Moran, J. H. (2013) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12216 · Cited by 96
Self-citationChimalakonda, K. C., Moran, C. L., Kennedy, P. D., et al. (2011) · Analytical Chemistry · doi:10.1021/ac201377m · Cited by 96
Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol.
Bornheim, L. M., Lasker, J. M., & Raucy, J. L. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08572-1 · Cited by 95
Δ9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice
Paronis, C. A., Nikas, S. P., Shukla, V. G., & Makriyannis, A. (2012) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32835a7c4d · Cited by 94
Cannabinoid CB2 Receptors in Health and Disease
Patel, K. D., Davison, J. S., Pittman, Q. J., et al. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790980041 · Cited by 92
Chimalakonda, K. C., Bratton, S. M., Le, V.-H., Yiew, K. H., Dineva, A., Moran, C. L., James, L. P., Moran, J. H., & Radominska-p, A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040709 · Cited by 84
Self-citationGrigoryev, A., Melnik, A., Savchuk, S. A., et al. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.07.004 · Cited by 79
Jankovics, P., Váradi, A., Tölgyesi, L., et al. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.07.011 · Cited by 78
Järbe, T. U. C., Lamb, R. J., Lin, S., & Makriyannis, A. (2001) · Psychopharmacology · doi:10.1007/s002130100730 · Cited by 77
Chin, C., Murphy, J. W., Huffman, J. W., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35174-2 · Cited by 75
Beuck, S., Möller, I., Thomas, A., et al. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4931-5 · Cited by 74
Zhang, Q., Ma, P., Cole, R. B., & Wang, G. (2006) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-006-0717-6 · Cited by 71
Wiley, J. L., Huffman, J. W., Balster, R. L., & Martin, B. R. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01193-5 · Cited by 70
Wiebelhaus, J. M., Poklis, J. L., Poklis, A., Vann, R. E., Lichtman, A. H., & Wise, L. E. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.05.034 · Cited by 69
Gamaleddin, I., Zvonok, A. M., Makriyannis, A., Goldberg, S. R., & Foll, B. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029900 · Cited by 65
Justinová, Z., Yaşar, S., Redhi, G. H., & Goldberg, S. R. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6058-10.2011 · Cited by 65
Watanabe, K., Matsunaga, T., YAMAMOTO, I., Funae, Y., & Yoshimura, H. (1995) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.18.1138 · Cited by 64
ElSohly, M. A., Gul, W., ElSohly, K. M., et al. (2011) · Journal of Analytical Toxicology · doi:10.1093/anatox/35.7.487 · Cited by 63
Presley, B. C., Jansen‐Varnum, S. A., & Logan, B. K. (2013) · PubMed · Cited by 61
Synthetic Cannabinoids and Cathinones: Prevalence and Markets.
Bretteville‐Jensen, A. L., Tuv, S. S., Bilgrei, O. R., Fjeld, B., & Bachs, L. C. (2013) · PubMed · Cited by 60
Brents, L. K., Zimmerman, S. M., Saffell, A., Prather, P. L., & Fantegrossi, W. E. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.206003 · Cited by 56
Self-citationGhisleni, G., Kazlauckas, V., Both, F. L., Pagnussat, N., Mioranzza, S., da Rocha, J. B. T., Souza, D. O., & Porciúncula, L. O. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.008 · Cited by 51
Hrubá, L., Ginsburg, B. C., & McMahon, L. R. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.196444 · Cited by 47
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940
Huffman, J. W., Thompson, A. L. S., Wiley, J. L., & Martin, B. R. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.09.033 · Cited by 39
Behavioural and gene transcription alterations induced by spontaneous cannabinoid withdrawal in mice
Oliva, J. M., Ortiz, S., Palomo, T., & Manzanares, J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01627.x · Cited by 37
Franklin, J. M., & Carrasco, G. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.454843 · Cited by 34
Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study
Pavanello, S., Fedeli, U., Mastrangelo, G., Rota, F., Overvad, K., Raaschou‐Nielsen, O., Tjønneland, A. M., & Vogel, U. B. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.02.004 · Cited by 34
Zhang, Q. L., Ma, P., Iszard, M., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1077 · Cited by 32
Järbe, T. U. C., Li, C., Vadivel, S. K., & Makriyannis, A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1708-z · Cited by 30
Cannabinoid 2 receptor- and beta Arrestin 2-dependent upregulation of serotonin 2A receptors
Franklin, J., Vasiljevik, T., Prisinzano, T. E., & Carrasco, G. A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.012 · Cited by 26
Morgan, D., Kondabolu, K., Kuipers, A., Sakhuja, R., Robertson, K. L., Rowland, N. E., & Booth, R. G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.051 · Cited by 21
Lovett, D. P., Yanes, E. G., Herbelin, T. W., et al. (2013) · Forensic Science International · doi:10.1016/j.forsciint.2012.12.012 · Cited by 20
Cited by
Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
Krishna Kumar, K., Shalev-Benami, M., Robertson, M. J., Hu, H., Banister, S. D., Hollingsworth, S. A., Latorraca, N. R., Kato, H. E., Hilger, D., Maeda, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.040 · Cited by 419
New psychoactive substances: challenges for drug surveillance, control, and public health responses
Peacock, A., Bruno, R., Gisev, N., Degenhardt, L., Hall, W., Sedefov, R., White, J., Thomas, K. V., Farrell, M., & Griffiths, P. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32231-7 · Cited by 360
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
Gracia-Lor, E., Castiglioni, S., Bade, R., Been, F., Castrignanò, E., Covaci, A., González-Mariño, I., Hapeshi, E., Kasprzyk-Hordern, B., Kinyua, J., et al. (2017) · Environment International · doi:10.1016/j.envint.2016.12.016 · Cited by 289
Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal
Cooper, Z. D. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0694-1 · Cited by 253
Metadata
- Authors
- Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A., & Prather, P. L.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 97
- Issue
- 1
- Pages
- 45-54
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2041841378
- Cited by
- 261
- References
- 101
- FWCI
- 30.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.